{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T03:27:07Z","timestamp":1786505227015,"version":"build-2736575974"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.prp.2026.156617","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:01:27Z","timestamp":1783440087000},"page":"156617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The cancer\/testis antigens represent promising targets for the development of new therapies against melanoma"],"prefix":"10.1016","volume":"286","author":[{"given":"Suzana Lemke","family":"Lanius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna Silveira","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Severo Sabedra","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eduarda","family":"Ehlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina Gessinger","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago Veiras","family":"Collares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana K\u00f6mmling","family":"Seixas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2026.156617_bib1","doi-asserted-by":"crossref","unstructured":"Iarc (2020) pr311_E. \u3008https:\/\/doi.org\/10.1001\/jamadermatol.2022.0160\u3009.","DOI":"10.1001\/jamadermatol.2022.0160"},{"key":"10.1016\/j.prp.2026.156617_bib2","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jid.2016.01.035","article-title":"The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031","volume":"136","author":"Whiteman","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.prp.2026.156617_bib3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.prp.2026.156617_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/CM9.0000000000003416","article-title":"Recent global patterns in skin cancer incidence, mortality, and prevalence","volume":"138","author":"Wang","year":"2025","journal-title":"Chin. Med. J. (Engl. )"},{"key":"10.1016\/j.prp.2026.156617_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","article-title":"Cutaneous melanoma","volume":"402","author":"Long","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.prp.2026.156617_bib6","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2394252","article-title":"Immunotherapy and delivery systems for melanoma","volume":"20","author":"Liu","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.prp.2026.156617_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020028454","article-title":"Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment","volume":"30","author":"Ahmed","year":"2020","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"10.1016\/j.prp.2026.156617_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.hoc.2018.09.005","article-title":"Cutaneous Melanoma-A Review in Detection, Staging, and Management","volume":"33","author":"Hartman","year":"2019","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"10.1016\/j.prp.2026.156617_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hemonc.2021.11.001","article-title":"Radiotherapy and Immunotherapy in Melanoma Brain Metastases","volume":"16","author":"Anvari","year":"2023","journal-title":"Hematol. Oncol. Stem Cell. Ther."},{"key":"10.1016\/j.prp.2026.156617_bib10","doi-asserted-by":"crossref","DOI":"10.61409\/V10240698","article-title":"Melanoma","author":"Mogensen","year":"2025","journal-title":"Ugeskr. Laege 187"},{"key":"10.1016\/j.prp.2026.156617_bib11","doi-asserted-by":"crossref","DOI":"10.4110\/in.2022.22.e2","article-title":"Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy","volume":"22","author":"Lee","year":"2022","journal-title":"Immune Netw."},{"key":"10.1016\/j.prp.2026.156617_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107889","article-title":"A novel era of cancer\/testis antigen in cancer immunotherapy","volume":"98","author":"Meng","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.prp.2026.156617_bib13","first-page":"7002","article-title":"The expression, modulation and use of cancer-testis antigens as potential biomarkers for cancer immunotherapy","volume":"12","author":"Li","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.prp.2026.156617_bib14","article-title":"Cancer testis antigen subfamilies: Attractive targets for therapeutic vaccine (Review)","volume":"62","author":"Shengnan","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.prp.2026.156617_bib15","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.prp.2026.156617_bib16","first-page":"9","article-title":"Epidemiology of Melanoma","volume":"9","author":"Saginala","year":"2021","journal-title":"Med. Sci. 2021"},{"key":"10.1016\/j.prp.2026.156617_bib17","article-title":"Cutaneous melanoma","volume":"11","author":"Tasdogan","year":"2025","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.prp.2026.156617_bib18","unstructured":"C\u00e2ncer de pele melanoma \u2014 Instituto Nacional de C\u00e2ncer - INCA. \u3008https:\/\/www.gov.br\/inca\/pt-br\/assuntos\/cancer\/tipos\/pele-melanoma\u3009. Accessed 8 Feb 2026."},{"key":"10.1016\/j.prp.2026.156617_bib19","unstructured":"-Ul-Ain Q., Ismail M. (2020) Metastatic melanoma-A review of current and future perspective. ArXiv arXiv:2003.04537."},{"key":"10.1016\/j.prp.2026.156617_bib20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00292-020-00776-x","article-title":"[Malignant melanoma]","volume":"41","author":"Lodde","year":"2020","journal-title":"Pathologe"},{"key":"10.1016\/j.prp.2026.156617_bib21","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.hoc.2024.05.005","article-title":"Nevi and Melanoma","volume":"38","author":"Zhang","year":"2024","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"10.1016\/j.prp.2026.156617_bib22","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01854-3","article-title":"Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches","volume":"22","author":"Hasan","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2026.156617_bib23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/CCO.0b013e3283252fc5","article-title":"Indoor ultraviolet tanning and skin cancer: health risks and opportunities","volume":"21","author":"Schulman","year":"2009","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.prp.2026.156617_bib24","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.mcna.2015.06.002","article-title":"Skin cancer epidemiology, detection, and management","volume":"99","author":"Gandhi","year":"2015","journal-title":"Med. Clin. North. Am."},{"key":"10.1016\/j.prp.2026.156617_bib25","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-019-0607-8","article-title":"Targeted therapy and immunotherapy for melanoma in Japan","volume":"20","author":"Namikawa","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.prp.2026.156617_bib26","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156617_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156617_bib28","unstructured":"Radiation: Ultraviolet (UV) radiation and skin cancer. \u3008https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/radiation-ultraviolet\u3009-(uv)-radiation-and-skin-cancer. Accessed 8 Feb 2026."},{"key":"10.1016\/j.prp.2026.156617_bib29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/ITT.S134842","article-title":"Melanoma treatment in review","volume":"7","author":"Domingues","year":"2018","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.prp.2026.156617_bib30","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3390\/cancers16050843","article-title":"Study on the Complex Melanoma","volume":"16","author":"Fateeva","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156617_bib31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.mehy.2018.05.002","article-title":"Functionalized nanoliposomes loaded with anti survivin and anti angiogenic agents to enhance the activity of chemotherapy against melanoma by 4-pronged action","volume":"116","author":"Mishra","year":"2018","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.prp.2026.156617_bib32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156617_bib33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.coms.2021.11.010","article-title":"Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma","volume":"34","author":"Ponto","year":"2022","journal-title":"Oral. Maxillofac. Surg. Clin. North. Am."},{"key":"10.1016\/j.prp.2026.156617_bib34","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.semcancer.2019.08.002","article-title":"Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment","volume":"59","author":"Marzagalli","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.prp.2026.156617_bib35","article-title":"Histology, T-Cell Lymphocyte","author":"Sauls","year":"2023","journal-title":"StatPearls"},{"key":"10.1016\/j.prp.2026.156617_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1448489","article-title":"Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy","volume":"15","author":"Laila","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156617_bib37","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev-pharmtox-011112-140326","article-title":"Cause and consequence of cancer\/testis antigen activation in cancer","volume":"54","author":"Whitehurst","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.prp.2026.156617_bib38","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.trecan.2018.08.005","article-title":"Emerging Contributions of Cancer\/Testis Antigens to Neoplastic Behaviors","volume":"4","author":"Gibbs","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.prp.2026.156617_bib39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.semcancer.2018.08.006","article-title":"Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy","volume":"53","author":"Gordeeva","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.prp.2026.156617_bib40","article-title":"Peptide-based vaccine for cancer therapies","volume":"14","author":"Buonaguro","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156617_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cells12060926","article-title":"Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer","volume":"12","author":"Nin","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.prp.2026.156617_bib42","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"Van Der Bruggen","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.prp.2026.156617_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkn673","article-title":"CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens","volume":"37","author":"Almeida","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.prp.2026.156617_bib44","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/CMR.0000000000000569","article-title":"Expression of cancer\/testis antigens in cutaneous melanoma: a systematic review","volume":"29","author":"Tio","year":"2019","journal-title":"Melanoma Res."},{"key":"10.1016\/j.prp.2026.156617_bib45","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2026.156617_bib46","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrm2858","article-title":"Genomic instability--an evolving hallmark of cancer","volume":"11","author":"Negrini","year":"2010","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.prp.2026.156617_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2025.103818","article-title":"Pathological modulation of genome maintenance by cancer\/testes antigens (CTAs)","volume":"147","author":"Vaziri","year":"2025","journal-title":"DNA Repair. (Amst. )"},{"key":"10.1016\/j.prp.2026.156617_bib48","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2217\/imt-2017-0083","article-title":"Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy","volume":"9","author":"Faramarzi","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.prp.2026.156617_bib49","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/08820139.2016.1197241","article-title":"Cancer\/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers","volume":"45","author":"Salmaninejad","year":"2016","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.prp.2026.156617_bib50","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1158\/0008-5472.CAN-08-2132","article-title":"The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis","volume":"68","author":"Liu","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2026.156617_bib51","first-page":"8840","article-title":"Comprehensive functional characterization of cancer\u2013testis antigens defines obligate participation in multiple hallmarks of cancer","volume":"6","author":"Maxfield","year":"2015","journal-title":"Nat. Commun. 2015"},{"key":"10.1016\/j.prp.2026.156617_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008759","article-title":"Single-cell sequencing unveils extensive intratumoral heterogeneity of cancer\/testis antigen expression in melanoma and lung cancer","volume":"12","author":"Traynor","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2026.156617_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2025.120687","article-title":"Cancer-testis antigens (CTAs) in lung cancer","volume":"579","author":"Talele","year":"2026","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.prp.2026.156617_bib54","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/14737159.2024.2347484","article-title":"Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios","volume":"24","author":"Roccuzzo","year":"2024","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"10.1016\/j.prp.2026.156617_bib55","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.88647","article-title":"Predictive Biomarkers in Cancer Immunotherapy: A Narrative Review Across Selected Solid Tumors","author":"Puntambekar","year":"2025","journal-title":"Cureus 17"},{"key":"10.1016\/j.prp.2026.156617_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218359","article-title":"Emerging biomarkers in melanoma: Bridging molecular discovery and precision oncology","volume":"645","author":"Xu","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2026.156617_bib57","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2026.156617_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188558","article-title":"Oncogenic cancer\/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy","volume":"1876","author":"Yang","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.prp.2026.156617_bib59","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1158\/2326-6066.CIR-13-0088","article-title":"Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers","volume":"2","author":"Yao","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.prp.2026.156617_bib60","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/j.1365-2133.2004.06260.x","article-title":"Melanoma or not? Cancer testis antigens may help","volume":"151","author":"L\u00fcftl","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.prp.2026.156617_bib61","first-page":"334","article-title":"Preferentially Expressed Antigen in Melanoma Is a Multifaceted Cancer Testis Antigen with Diverse Roles as a Biomarker and Therapeutic Target","volume":"3","author":"Bose","year":"2023","journal-title":"Int. J. Transl. Med. 2023"},{"key":"10.1016\/j.prp.2026.156617_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154543","article-title":"Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases","volume":"247","author":"Broggi","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.prp.2026.156617_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031582","article-title":"PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer","volume":"25","author":"Cassalia","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156617_bib64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/DAD.0000000000002863","article-title":"The Utility of PRAME and Ki-67 as Prognostic Markers for Cutaneous Melanoma","volume":"47","author":"Asato","year":"2025","journal-title":"Am. J. Dermatopathol."},{"key":"10.1016\/j.prp.2026.156617_bib65","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/cup.14438","article-title":"Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma","volume":"50","author":"Bahmad","year":"2023","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.prp.2026.156617_bib66","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/PAS.0000000000001393","article-title":"Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma","volume":"44","author":"Lezcano","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2026.156617_bib67","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-10-3","article-title":"Improvement of different vaccine delivery systems for cancer therapy","volume":"10","author":"Bolhassani","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2026.156617_bib68","doi-asserted-by":"crossref","first-page":"15772","DOI":"10.18632\/oncotarget.4694","article-title":"Oncogenic cancer\/testis antigens: prime candidates for immunotherapy","volume":"6","author":"Gjerstorff","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.prp.2026.156617_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/j.1755-148X.2008.00535.x","article-title":"Browsing issues","volume":"22","author":"Goding","year":"2009","journal-title":"Pigment. Cell. Melanoma Res."},{"key":"10.1016\/j.prp.2026.156617_bib70","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41568-022-00544-4","article-title":"Mechanisms driving the immunoregulatory function of cancer cells","volume":"23","author":"van Weverwijk","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2026.156617_bib71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/bs.pmbts.2024.03.001","article-title":"Rational design of adjuvants boosts cancer vaccines","volume":"209","author":"Li","year":"2024","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.prp.2026.156617_bib72","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1158\/0008-5472.CAN-07-1478","article-title":"MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2026.156617_bib73","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.molcel.2010.08.029","article-title":"MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases","volume":"39","author":"Doyle","year":"2010","journal-title":"Mol. Cell."},{"key":"10.1016\/j.prp.2026.156617_bib74","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S","article-title":"Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1","volume":"80","author":"Marchand","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2026.156617_bib75","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1158\/0008-5472.CAN-07-5898","article-title":"Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities","volume":"68","author":"Connerotte","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2026.156617_bib76","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1200\/JCO.2012.43.7111","article-title":"Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma","volume":"31","author":"Kruit","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156617_bib77","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2026.156617_bib78","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-020-02306-y","article-title":"Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy","volume":"18","author":"Raza","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.prp.2026.156617_bib79","first-page":"11","article-title":"Expression of the cancer\/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM) - correlation with prognostic factors","volume":"7","author":"Velazquez","year":"2007","journal-title":"Cancer Immunity a Journal Academy Cancer Immunology"},{"key":"10.1016\/j.prp.2026.156617_bib80","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/761378","article-title":"Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+ T Cells in Cutaneous Melanoma","volume":"2015","author":"Giavina-Bianchi","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.prp.2026.156617_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/psc.70022","article-title":"Vivo Evaluation of Pam2Cys-Modified Cancer-Testis Antigens as Potential Self-Adjuvanting Cancer Vaccines","volume":"31","author":"Aljohani","year":"2025","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.prp.2026.156617_bib82","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1216290","article-title":"Vaccination of stage III\/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope","volume":"5","author":"Baumgaertner","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.prp.2026.156617_bib83","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0345-7","article-title":"Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis","volume":"6","author":"Lattanzi","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2026.156617_bib84","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156617_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111434","article-title":"A comprehensive review of PRAME and BAP1 in melanoma: Genomic instability and immunotherapy targets","volume":"124","author":"Aljabali","year":"2024","journal-title":"Cell. Signal."},{"key":"10.1016\/j.prp.2026.156617_bib86","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-025-07259-8","article-title":"Innovative gene engineering strategies to address tumor antigen escape in cell therapy","volume":"23","author":"Chen","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.prp.2026.156617_bib87","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00008390-200110000-00003","article-title":"Expression profile of genes coding for melanoma differentiation antigens and cancer\/testis antigens in metastatic lesions of human cutaneous melanoma","volume":"11","author":"Zendman","year":"2001","journal-title":"Melanoma Res."},{"key":"10.1016\/j.prp.2026.156617_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101418","article-title":"Epitope prediction and identification- adaptive T cell responses in humans","volume":"50","author":"Sidney","year":"2020","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.prp.2026.156617_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.105057","article-title":"An overview of progress from empirical to rational design in modern vaccine development, with an emphasis on computational tools and immunoinformatics approaches","volume":"140","author":"Soleymani","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.prp.2026.156617_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105872","article-title":"Production, purification, and in vivo evaluation of a novel multiepitope peptide vaccine consisted of immunodominant epitopes of SYCP1 and ACRBP antigens as a prophylactic melanoma vaccine","volume":"76","author":"Safavi","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.prp.2026.156617_bib91","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3390\/cimb47060443","article-title":"Xenogeneic Testicular Cell Vaccination Induces Long-Term Anti-Cancer Immunity in Mice","volume":"47","author":"Seledtsov","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.prp.2026.156617_bib92","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/jcp.10215","article-title":"Cancer\/testis-associated genes: identification, expression profile, and putative function","volume":"194","author":"Zendman","year":"2003","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.prp.2026.156617_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000101","article-title":"Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers","volume":"39","author":"Park","year":"2016","journal-title":"J. Immunother."},{"key":"10.1016\/j.prp.2026.156617_bib94","article-title":"Designing, cloning and simulation studies of cancer\/testis antigens based multi-epitope vaccine candidates against cutaneous melanoma: An immunoinformatics approach","volume":"37","author":"Khalid","year":"2024","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.prp.2026.156617_bib95","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/bs.podrm.2015.12.002","article-title":"Dacarbazine","volume":"41","author":"Al-Badr","year":"2016","journal-title":"Profiles Drug. Subst. Excip. Relat. Methodol."},{"key":"10.1016\/j.prp.2026.156617_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000203","article-title":"Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I\/II study with a first assessment of a predictive gene signature","volume":"2","author":"Grob","year":"2017","journal-title":"ESMO Open."},{"key":"10.1016\/j.prp.2026.156617_bib97","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00262-011-1024-4","article-title":"Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2\u2019-Deoxycytidine","volume":"60","author":"Yan","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.prp.2026.156617_bib98","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/2326-6066.CIR-19-0545","article-title":"Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma","volume":"8","author":"Pavlick","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.prp.2026.156617_bib99","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1097\/JTO.0000000000000653","article-title":"Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with or without adjuvant chemotherapy in patients with resected stage IB to III MAGE-A3-positive non-small-cell lung cancer","volume":"10","author":"Pujol","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2026.156617_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101821","article-title":"Epigenetic modifications: Key players in cancer heterogeneity and drug resistance","volume":"39","author":"Sadida","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.prp.2026.156617_bib101","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.7150\/jca.24577","article-title":"Current status and future directions of cancer immunotherapy","volume":"9","author":"Zhang","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.prp.2026.156617_bib102","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005684","article-title":"Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma","volume":"10","author":"Khushalani","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2026.156617_bib103","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/s41388-018-0357-2","article-title":"Massive expression of germ cell-specific genes is a hallmark of cancer and a potential target for novel treatment development","volume":"37","author":"Bruggeman","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2026.156617_bib104","article-title":"Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156617_bib105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.oraloncology.2016.05.008","article-title":"Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells","volume":"58","author":"Concha-Benavente","year":"2016","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.prp.2026.156617_bib106","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156617_bib107","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.prp.2026.156617_bib108","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/586314","article-title":"TCR gene transfer: MAGE-C2\/HLA-A2 and MAGE-A3\/HLA-DP4 epitopes as melanoma-specific immune targets","volume":"2012","author":"Straetemans","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.prp.2026.156617_bib109","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J. Immunother."},{"key":"10.1016\/j.prp.2026.156617_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093321","article-title":"Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer","volume":"9","author":"Abate-Daga","year":"2014","journal-title":"PLoS. One"},{"key":"10.1016\/j.prp.2026.156617_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2017.00018","article-title":"MAGE-A Antigens and Cancer Immunotherapy","volume":"4","author":"Zajac","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.prp.2026.156617_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156617_bib113","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070984","article-title":"Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?","volume":"11","author":"Al-Khadairi","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156617_bib114","first-page":"3630","article-title":"Generation of NY-ESO-1-specific CD4+ and CD8+ T Cells by a Single Peptide with Dual MHC Class I and Class II Specificities: A New Strategy for Vaccine Design","volume":"62","author":"Zeng","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2026.156617_bib115","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:34:32Z","timestamp":1786502072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826002700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":115,"alternative-id":["S0344033826002700"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156617","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cancer\/testis antigens represent promising targets for the development of new therapies against melanoma","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"156617"}}